Please login to the form below
Eli Lily
This page shows the latest Eli Lily news and features for those working in and with pharma, biotech and healthcare.
Biohaven gets FDA approval for migraine drug Nurtec ODT
Once launched it will also have to compete with Eli Lily’s new acute migraine therapy Reyvow (lasmiditan), a first-in-class 5H-T.
Latest news
-
Nine positive opinions for new drugs at CHMP meeting
Another medicine for lung cancer, Portrazza (necitumumab) from Eli Lilly, was also backed by the CHMP for the treatment of squamous NSCLC.
-
Building brand strength – Part 1
We have seen products such as Viagra, Prilosec and Lipitor along with some corporate names (eg, Eli Lily, Pfizer and Merck) nominated in our Iconic Brands survey.
-
Positive phase IV results for Zyvox
Data from the study showed that Zyvox achieved a statistically significantly higher clinical success rate compared with vancomycin, which was first marketed as vancomycin hydrochloride by Eli Lily under the trade
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Holding on to hope for Alzheimer’s advances
Both analysts and academics had been getting excited about the Expedition 3 trial of Eli Lilly’s solanezumab, which has been developed to target amyloid-beta - the protein that clumps together
-
Who tops the pharma list?
For example, patents for Seroquel (AstraZeneca - 2011 revenues of $5.8bn), Zyprexa (Eli Lily - $4.6bn) and Concerta (J&J - $1.3bn) had all expired by May 2012.
-
The rise of chronic disease in BRIC markets
In July 2012, Eli Lilly opened a diabetes research centre in Shanghai. ... These include GSK's alliance with Binnopharm in Russia, Roche's partnership with Encure Pharmaceuticals to develop affordable versions of Herceptin and MabThera in India, and Eli
More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Create Health
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
